Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era.

ABSTRACT:

Background

Pre-exposure prophylaxis for COVID-19 with tixagevimab/cilgavimab (T/C) received Emergency Use Authorization (EUA) based on results of a clinical trial conducted prior to the emergence of the Omicron variant. The clinical effectiveness of T/C has not been well described in the Omicron era. We examined the incidence of symptomatic illness and hospitalizations among T/C recipients when Omicron accounted for virtually all local cases.

Methods

Through retrospective electronic medical record chart review, we identified patients who received T/C between January 1 -July 31, 2022 within our quaternary referral health system. We determined the incidence of symptomatic COVID-19 infections and hospitalizations due to or presumed to be caused by early Omicron variants before

SUBMITTER: Chen B 

PROVIDER: S-EPMC10138227 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature